Építés alatt – nem éles oldal
Belépés
BefejeződöttFázis nélkül

The Role of the Circadian System in Binge Eating Disorder

A legfontosabb adatok

Ki végzi
University of Cincinnati
Hol
Mason (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Befejeződött
Résztvevők
84 fő vett részt
Kezdés
2021. jan. 15.
Befejezés
2025. máj. 30.
A vizsgálat típusa
Beavatkozással járó, 3 csoportAz egyik csoport nem kap vizsgálati kezelést, összehasonlításként.
A vizsgált kezelések
  • Melatonin (3hrs before DLMO)
  • Placebo (3hrs before DLMO)
  • Morning light version 1
  • Morning light version 2
A regiszteradat frissítve
2026. augusztus 21.

Ki vehet részt

Életkor
18 év – 50 év
Nem
Nők és férfiak
Egészséges önkéntesek
Részt vehetnek

A regiszter feltételei, szó szerint

Mind a 42 feltétel megnézéseKevesebb

Egyéb feltételek

  • Binge Eating Disorder (BED) group inclusion criteria:
  • Age 18-50 years, inclusive
  • Female or male
  • BMI ≥30 kg/m2
  • Current BED diagnoses by Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) criteria confirmed by Structured Clinical Interview (SCID-5)
  • Moderate or severe BED (≥3 binge eating episodes/week in the past 14 days)
  • No current pharmacological treatment for BED, or if receiving treatment dose stable for ≥ 2 months
  • If receiving psychotherapy, intervention must be stable for ≥ 3 months and agree to continue during the study
  • Other psychiatric disorders will be permitted as long as they are not more than moderate in severity
  • Using an effective contraceptive method (participants of childbearing potential); BED exclusion criteria:
  • Current severe comorbid psychopathology (i.e; mania, severe major depressive disorder (MDD), psychosis)
  • Current (past month) substance use disorder (caffeine and nicotine allowed)
  • Chronic use of bright light therapy (BLT) or melatonin in the past month
  • Current contraindication or history of melatonin allergy or non-tolerability
  • Current contraindication or history of BLT non-tolerability
  • Significant risk of suicide according to Columbia-Suicide Severity Rating Scale (CSSRS) or clinical judgment, or suicidal behavior in the past year
  • Routine shift work (night work) in the past month
  • Travel across more than 1 time zone in the past two weeks
  • Current treatment with medication known to affect the circadian system or melatonin measurements, including: B-blockers, hypnotic sedatives, anticoagulants, antidiabetes drugs, oral corticosteroids, and other immunosuppressant medication
  • Current lesions or bleeding in the oral cavity, as it may alter DLMO measurements
  • Clinically significant unstable medical conditions as judged by the clinician, including: seizure or neurodegenerative disorders, thyroid conditions, autoimmune disorders, and cardiovascular disease
  • Pregnancy or breastfeeding
  • Participation in a clinical trial in the past month
  • Suspected intelligence quotient (IQ) <80
  • Any other clinically relevant reason as judged by the clinician; Control group inclusion criteria:
  • Age 18-50 years, inclusive
  • Female or male
  • BMI ≥30 kg/m2
  • No current or lifetime history of BED or bulimia nervosa diagnoses confirmed by SCID-5
  • No current (past month) psychiatric diagnosis according to SCID-5, including substance use disorders (caffeine and nicotine allowed)
  • No current psychiatric or psychological treatment, or if receiving treatment dose/intervention stable for ≥ 2 months; Control group exclusion criteria:
  • Clinically significant unstable medical conditions as judged by the clinician, including: seizure or neurodegenerative disorders, thyroid conditions, autoimmune disorders, and cardiovascular disease
  • Chronic treatment with BLT or melatonin in the past month
  • Routine shift work (work at night) in the past month
  • Travel across more than 1 time zone in the past two weeks
  • Significant risk of suicide according to CSSRS or clinical judgment, or suicidal behavior in the past year
  • Current treatment with medication known to affect the circadian system or melatonin measurements, including, B-blockers, hypnotic sedatives, anticoagulants, antidiabetes drugs, oral corticosteroids, and other immunosuppressant medication
  • Current lesions or bleeding in the oral cavity, as it may alter DLMO measurements
  • Pregnant or breastfeeding
  • Participation in a clinical trial in the past month
  • Suspected IQ<80
  • Any other clinically relevant reason as judged by the clinician

Helyszínek itt: Egyesült Államok

  • Lindner Center of HOPE / University of CincinnatiMason, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

Binge eating disorder (BED) shows prominent circadian features that suggest a delay in circadian phase, and preliminary evidence shows binge eating may be responsive to chronobiological interventions, implicating a circadian system dysfunction in its pathophysiology. What remains lacking, however, is comprehensive knowledge of the characteristics of circadian system dysfunction in BED, and whether this dysfunction represents a therapeutic target in BED. There is therefore a critical need to characterize circadian system dysfunction in BED, and evaluate it as a potential therapeutic target. Without such information, the understanding on the role of the circadian system in BED and its potential as a new therapeutic target will remain limited.

A vizsgálat 3 csoportja

  • Morning light version+ MelatoninEgyéb csoport

    Morning light version and melatonin 3mg capsule (3hrs before DLMO)

    Kezelés: Melatonin (3hrs before DLMO) és Morning light version 1

  • Morning light version+ PlaceboEgyéb csoport

    Morning light version and placebo capsule (3hrs before DLMO)

    Kezelés: Placebo (3hrs before DLMO) és Morning light version 2

  • Control groupNincs vizsgálati kezelés, összehasonlításként

    Adults with obesity without BED, only phase1 and did not receive intervention

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
A regiszteradat frissítve
2026. augusztus 21.